Haemonetics Corporation (NYSE:HAE) Director Mark W. Kroll sold 7,118 shares of Haemonetics stock in a transaction that occurred on Tuesday, January 2nd. The stock was sold at an average price of $63.00, for a total value of $448,434.00. Following the transaction, the director now owns 33,881 shares in the company, valued at approximately $2,134,503. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.
Haemonetics Corporation (NYSE HAE) traded down $0.47 during mid-day trading on Wednesday, reaching $62.63. The company’s stock had a trading volume of 428,066 shares, compared to its average volume of 913,900. The company has a debt-to-equity ratio of 0.22, a quick ratio of 1.51 and a current ratio of 2.17. The firm has a market capitalization of $3,310.00, a PE ratio of 894.71, a price-to-earnings-growth ratio of 4.37 and a beta of 0.99. Haemonetics Corporation has a one year low of $36.44 and a one year high of $63.90.
Haemonetics (NYSE:HAE) last posted its earnings results on Tuesday, November 7th. The medical instruments supplier reported $0.48 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.41 by $0.07. The company had revenue of $225.40 million during the quarter, compared to analysts’ expectations of $219.12 million. Haemonetics had a return on equity of 11.16% and a net margin of 0.50%. The firm’s quarterly revenue was up 2.3% compared to the same quarter last year. During the same quarter last year, the firm earned $0.38 earnings per share. analysts predict that Haemonetics Corporation will post 1.7 EPS for the current fiscal year.
HAE has been the topic of a number of analyst reports. Zacks Investment Research upgraded Haemonetics from a “hold” rating to a “buy” rating and set a $52.00 price objective on the stock in a research report on Wednesday, October 25th. Morgan Stanley raised their target price on Haemonetics from $43.00 to $51.00 and gave the stock an “equal weight” rating in a research note on Thursday, November 9th. Barrington Research raised their target price on Haemonetics from $48.00 to $57.00 and gave the stock an “outperform” rating in a research note on Wednesday, November 8th. Craig Hallum reissued a “hold” rating and set a $50.00 target price (up previously from $40.00) on shares of Haemonetics in a research note on Wednesday, November 8th. Finally, Raymond James Financial raised Haemonetics from an “underperform” rating to a “market perform” rating in a research note on Tuesday. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and four have given a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and an average price target of $53.33.
WARNING: This piece was originally posted by American Banking News and is owned by of American Banking News. If you are accessing this piece on another site, it was stolen and republished in violation of international copyright & trademark laws. The legal version of this piece can be viewed at https://www.americanbankingnews.com/2018/01/03/mark-w-kroll-sells-7118-shares-of-haemonetics-corporation-hae-stock.html.
Haemonetics Corporation (Haemonetics) is a healthcare company. The Company provides various products to customers involved in the processing, handling and analysis of blood. The Company’s segments include Japan, EMEA, North America Plasma and All Other. Haemonetics provides plasma collection systems and software, which enable plasma fractionators to make pharmaceuticals.
Receive News & Ratings for Haemonetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Haemonetics and related companies with MarketBeat.com's FREE daily email newsletter.